1. The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial

Volume 18, Issue 6, June 2017, Pages 1555-1560

Georg Holgersson; Michael Bergqvist; Jonas Nilsson; Marcus Thuresson; Johan Harmenberg; Stefan Bergstrom

• View Article
• PDF 549.94 K

2. Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status

Volume 14, Issue 5, May 2013, Pages 3255-3261

• View Article
• PDF 463.8 K

3. Comparison of the Efficacy and Safety of EFGR TyrosineKinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis

Volume 13, Issue 10, October 2012, Pages 5177-5182

• View Article
• PDF 575.91 K